Remove In-Vitro Remove Medicine Remove Reagent Remove Research
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells. This continues to be the standard of care.

article thumbnail

Roche provides molecular testing solutions to identify and differentiate SARS-CoV-2 Omicron variants of concern

The Pharma Data

Roche and its subsidiary, Tib Molbiol, confirm that it has tests for research use that identify the SARS-CoV-2 subvariants of concern, Omicron: BA.1, It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. 3 and Delta. “In

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

DS: What motivated you and Dr David Bunka, CTO, to create Aptamer and did you imagine you would one day be operating on such a global scale?    AT : We initially met at the University of Leeds, where David was a post-doctoral researcher studying aptamers, and I was completing my PhD. Optimer binders are engineered to overcome these problems.

article thumbnail

It’s My Party and I’ll Cry if I Want to: A Bittersweet Happy 30th Birthday to LDTs

FDA Law Blog

If anything, the announcement was remarkably inconspicuous: a seemingly throwaway sentence in a draft compliance policy guide for research use only and investigational use only products. Tests created by labs were important in 1992, but they play a far more vital role in medicine today.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

WeiQi Lin, MD, PhD, executive vice president of research & development and principal scientist, DURECT Corporation. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading business development in industry. Motivations for Transition. Key Moments.

article thumbnail

Transforming high-throughput screening with mass spectrometry

Drug Discovery World

HTS is widely used by pharmaceutical companies to identify compounds (or ‘hits’) that show pharmacological activity, which are used as starting points to optimise medicines during the drug discovery process. The rapid evolution of HTS to meet industry demand . Overcoming challenges in HTS using mass spectrometry .

Drugs 52